Taiwan · Delayed Price · Currency is TWD Advagene Biopharma Statistics
Total Valuation
TPEX:6709 has a market cap or net worth of TWD 1.51 billion. The enterprise value is 1.19 billion.
| Market Cap | 1.51B |
| Enterprise Value | 1.19B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6709 has 59.38 million shares outstanding. The number of shares has increased by 4.66% in one year.
| Current Share Class | 59.38M |
| Shares Outstanding | 59.38M |
| Shares Change (YoY) | +4.66% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.46% |
| Owned by Institutions (%) | 2.74% |
| Float | 26.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.25 |
| P/TBV Ratio | 4.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 44.32, with a Debt / Equity ratio of 0.01.
| Current Ratio | 44.32 |
| Quick Ratio | 41.05 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -640.99 |
Financial Efficiency
Return on equity (ROE) is -33.48% and return on invested capital (ROIC) is -21.12%.
| Return on Equity (ROE) | -33.48% |
| Return on Assets (ROA) | -20.63% |
| Return on Invested Capital (ROIC) | -21.12% |
| Return on Capital Employed (ROCE) | -25.96% |
| Weighted Average Cost of Capital (WACC) | 7.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.39% in the last 52 weeks. The beta is 0.66, so TPEX:6709's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | +15.39% |
| 50-Day Moving Average | 24.84 |
| 200-Day Moving Average | 27.70 |
| Relative Strength Index (RSI) | 49.53 |
| Average Volume (20 Days) | 121,146 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -92.94M |
| Pretax Income | -91.05M |
| Net Income | -91.05M |
| EBITDA | -90.29M |
| EBIT | -92.94M |
| Earnings Per Share (EPS) | -1.51 |
Balance Sheet
The company has 325.18 million in cash and 2.13 million in debt, with a net cash position of 323.05 million or 5.44 per share.
| Cash & Cash Equivalents | 325.18M |
| Total Debt | 2.13M |
| Net Cash | 323.05M |
| Net Cash Per Share | 5.44 |
| Equity (Book Value) | 356.43M |
| Book Value Per Share | 5.87 |
| Working Capital | 343.51M |
Cash Flow
In the last 12 months, operating cash flow was -87.92 million and capital expenditures -2.71 million, giving a free cash flow of -90.62 million.
| Operating Cash Flow | -87.92M |
| Capital Expenditures | -2.71M |
| Depreciation & Amortization | 2.66M |
| Net Borrowing | -1.88M |
| Free Cash Flow | -90.62M |
| FCF Per Share | -1.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6709 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.66% |
| Shareholder Yield | -4.66% |
| Earnings Yield | -6.01% |
| FCF Yield | -5.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |